Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care Conferences
Kane Biotech (KNBIF) presented significant preclinical data and clinical case studies for its revyve™ Antimicrobial Wound Gel at two major North American wound care conferences. The preclinical in vitro studies demonstrated remarkable protease inhibition, including 80% reduction in MMP activity, 82% reduction in elastase activity, and 100% reduction in collagenase and TACE enzyme activity.
Clinical case studies showed meaningful improvements in chronic wound patients, including wound size reduction, pain elimination, and improved tissue regranulation over 6-12 weeks. Notable cases included a 60% wound size reduction in a venous leg ulcer over two months and significant improvements in pressure wound cases.
Kane Biotech (KNBIF) ha presentato dati preclinici significativi e studi clinici su casi reali del suo revyve™ Antimicrobial Wound Gel in due importanti conferenze nordamericane dedicate alla cura delle ferite. Gli studi preclinici in vitro hanno evidenziato un'inibizione proteasica notevole, con una riduzione dell'80% dell'attività delle MMP, un'82% di riduzione dell'attività dell'elastasi e una riduzione del 100% dell'attività delle collagenasi e dell'enzima TACE.
Gli studi clinici su casi reali hanno mostrato miglioramenti significativi in pazienti con ferite croniche, tra cui la riduzione delle dimensioni della ferita, l'eliminazione del dolore e un miglioramento della rigenerazione tissutale in un arco di 6-12 settimane. Tra i casi più rilevanti si segnalano una riduzione del 60% delle dimensioni di un'ulcera venosa alla gamba in due mesi e miglioramenti importanti in casi di ferite da pressione.
Kane Biotech (KNBIF) presentó datos preclínicos significativos y estudios clínicos de casos para su revyve™ Antimicrobial Wound Gel en dos importantes conferencias norteamericanas sobre cuidado de heridas. Los estudios preclínicos in vitro demostraron una notable inhibición de proteasas, incluyendo una reducción del 80% en la actividad de MMP, una reducción del 82% en la actividad de elastasa y una reducción del 100% en la actividad de colagenasa y la enzima TACE.
Los estudios clínicos de casos mostraron mejoras significativas en pacientes con heridas crónicas, tales como reducción del tamaño de la herida, eliminación del dolor y mejor regranulación tisular durante 6-12 semanas. Casos destacados incluyeron una reducción del 60% del tamaño de una úlcera venosa en la pierna en dos meses y mejoras notables en casos de heridas por presión.
Kane Biotech (KNBIF)는 두 개의 주요 북미 상처 치료 컨퍼런스에서 revyve™ 항균 상처 겔에 대한 중요한 전임상 데이터와 임상 사례 연구를 발표했습니다. 전임상 시험(in vitro)에서는 단백질 분해효소 억제가 눈에 띄게 나타났으며, MMP 활성 80% 감소, 엘라스타제 활성 82% 감소, 콜라게나제 및 TACE 효소 활성 100% 감소를 보였습니다.
임상 사례 연구에서는 만성 상처 환자에서 상처 크기 감소, 통증 완화, 6~12주 동안 조직 재생 개선 등 의미 있는 개선이 확인되었습니다. 주목할 만한 사례로는 2개월 동안 정맥성 하지 궤양의 상처 크기 60% 감소와 욕창 환자에서의 현저한 개선이 포함됩니다.
Kane Biotech (KNBIF) a présenté des données précliniques significatives et des études de cas cliniques concernant son revyve™ Antimicrobial Wound Gel lors de deux grandes conférences nord-américaines sur les soins des plaies. Les études précliniques in vitro ont démontré une inhibition remarquable des protéases, incluant une réduction de 80 % de l'activité des MMP, une réduction de 82 % de l'activité de l'élastase et une réduction de 100 % de l'activité des enzymes collagénase et TACE.
Les études de cas cliniques ont montré des améliorations notables chez des patients souffrant de plaies chroniques, telles que la réduction de la taille de la plaie, l'élimination de la douleur et une meilleure regranulation tissulaire sur une période de 6 à 12 semaines. Parmi les cas remarquables, on compte une réduction de 60 % de la taille d’une ulcère veineuse de la jambe en deux mois et des améliorations significatives dans des cas de plaies de pression.
Kane Biotech (KNBIF) präsentierte bedeutende präklinische Daten und klinische Fallstudien zu seinem revyve™ Antimicrobial Wound Gel auf zwei großen nordamerikanischen Wundversorgungskonferenzen. Die präklinischen In-vitro-Studien zeigten bemerkenswerte Proteasehemmung, darunter eine 80%ige Reduktion der MMP-Aktivität, eine 82%ige Reduktion der Elastase-Aktivität und eine 100%ige Reduktion der Kollagenase- und TACE-Enzymaktivität.
Klinische Fallstudien zeigten bedeutende Verbesserungen bei Patienten mit chronischen Wunden, einschließlich der Verringerung der Wundgröße, Schmerzlinderung und verbesserter Geweberegeneration über 6 bis 12 Wochen. Bemerkenswerte Fälle umfassten eine 60%ige Verringerung der Wundgröße bei einem venösen Beingeschwür innerhalb von zwei Monaten sowie signifikante Verbesserungen bei Druckgeschwüren.
- None.
- Limited clinical data with only four case studies presented
- Early-stage clinical observations without large-scale controlled trials
- Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in chronic wound patients using revyve® over 6–12 weeks
- Preclinical in vitro studies demonstrated >
80% reduction in protease activity, including complete inhibition of TACE and collagenase — key factors in non-healing chronic wounds
- revyve® data featured in presentations and posters at NSWOCC and SAWC—two of the leading North American conferences on wound care
WINNIPEG, Manitoba, July 30, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane" or "Kane Biotech") recently presented novel preclinical data and clinical case observations at two major North American wound care conferences: Nurses Specialized in Wound, Ostomy and Continence Canada (NSWOCC) 44th National Conference (May 21–25, 2025), and the Symposium on Advanced Wound Care (SAWC) Spring Conference (April 30–May 4, 2025).
Preclinical data presented at SAWC, the largest wound care conference in the United States, highlighted the in vitro performance of revyve®, including inhibition of key proteases such as matrix metalloproteinases (MMPs), elastase, collagenase, and TNF-Alpha Converting Enzyme (TACE). In vitro models demonstrated:
80% reduction in MMP activity82% reduction in elastase activity100% reduction in collagenase and TACE enzyme activity
These data support ongoing scientific exploration into chronic wound mechanisms, including elevated levels of Tumor Necrosis Factor-alpha (TNF-α), which in chronic wounds may exceed those in acute wounds by up to 100-fold.
At the NSWOCC conference, Kane showcased four case study posters, delivered an oral presentation, and hosted a booth featuring revyve® Antimicrobial Wound Gel and the XSONX® wound hygiene system. The presentation, titled "Changing the Paradigm of Wound Care Through the Use of Novel Modalities," included speakers from clinical and industry backgrounds: Rosemary Hill, BSN, CWOCN, WOCC(C), Vancouver Coastal Health; John Garrettson, BA, CWCA, Strategic Commercial Technology Consultant, Kane Biotech; Dr. Rohan Pointer, MD, MSc, Medical Director, Medical Affairs, Kane Biotech; and Dr. Iris Noland, MD, MCISc, Lakeview Family Health Team.
“Since its approval by Health Canada, revyve® has been evaluated in a case series with encouraging results. It was shown to convert non-healing wounds to healing wounds in real patients with complex chronic lesions”, said Dr. Rohan Pointer, Medical Director, Kane Biotech.
The Canadian case study posters featured four unique clinical cases, part of a larger series, observing changes in wound size, pain, exudate, and tissue regranulation over time in patients with chronic, difficult-to-treat wounds. These included:
- Observed reduction in wound size over three weeks and reported quality of life improvement in a pressure wound case
60% wound size reduction over two months in a venous leg ulcer- Reported pain elimination and exudate reduction in a painful pressure wound
- Observed healing progression in a venous leg ulcer with associated pain improvement over six weeks
Dr. Pointer further commented, “At Kane, we are encouraged by the in vitro and early clinical observations shared at these conferences. These insights point to the potential role of revyve® in supporting wound hygiene and care for patients with complex lesions.”
Healthcare professionals attending both events engaged directly with Kane representatives, received educational materials, and participated in product demonstrations of revyve®.
“Clinical conferences are an opportunity for Kane to reinforce our innovation in wound care,” said Dr. Robert Huizinga, Interim CEO. “These presentations are an expansion of our market support plan for revyve® and demonstrate both the clinical value and commercial potential of revyve®. We look forward to presenting additional data throughout this year and next.”
About Kane Biotech
Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria.
For more information:
| Dr. Robert Huizinga | Ray Dupuis | |||
| Interim CEO | Chief Financial Officer | |||
| Kane Biotech Inc | Kane Biotech Inc | |||
| rhuizinga@kanebiotech.com | rdupuis@kanebiotech.com | |||
| (780) 970-1100 | (204) 298-2200 | |||
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
What were the key findings from Kane Biotech's (KNBIF) revyve™ clinical case studies?
What protease inhibition results did Kane Biotech's revyve™ demonstrate in preclinical studies?
Which wound care conferences featured Kane Biotech's (KNBIF) revyve™ presentations in 2025?
What types of wounds were treated in Kane Biotech's revyve™ case studies?
